Bacterial News and Research

RSS

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor.

26 Jun 2014

New wound treatment with material leads to faster healing, prevents harmful bacteria from sticking

As many patients know, treating wounds has become far more sophisticated than sewing stitches and applying gauze, but dressings still have shortcomings.

26 Jun 2014

Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Like all drugs, antibiotics can have side-effects when administered to people. The most common (and often benign) side effect people experience when taking antibiotics is “associated diarrhea”. This illustrates the fact that antibiotics have an impact on the intestine!

25 Jun 2014

Bruker receives CFDA clearance to market IVD MALDI Biotyper System in China

Bruker Corporation today announced that it has received clearance from the China Food and Drug Administration to market and sell its IVD MALDI Biotyper System as a medical device in China for the identification of microorganisms isolated from human specimens.

From Bruker 25 Jun 2014

Alcoholic liver disease: an interview with Dr Vinood Patel, University of Westminster

Alcoholic liver disease (ALD) is one of the leading causes of death worldwide and also in the UK. As its name indicates this disease arises due to consuming excessive amounts of alcohol (80 g/day) over an extended period, normally 10-20 years.

24 Jun 2014

Microparticles in crab, shrimp and lobster shells may help prevent inflammatory bowel disease

Yoshimi Shibata, Ph.D., professor of biomedical science in the Charles E. Schmidt College of Medicine at Florida Atlantic University, has received a $380,552 grant from the National Institute of Complementary and Alternative Medicine of the National Institutes of Health to further investigate how microparticles called "chitin" found in crab, shrimp and lobster shells have anti-inflammatory mechanisms that could lead to the development of novel preventive and therapeutic strategies for individuals who suffer from inflammatory bowel disease (IBD) and others diseases.

24 Jun 2014

Scientists turn to old class of antibiotics to fight superbugs resistant to modern medicine

Scientists at the University at Buffalo are turning to an old class of antibiotics to fight new superbugs resistant to modern medicine.

24 Jun 2014

Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Cubist Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration approved SIVEXTRO (tedizolid phosphate) for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI).

21 Jun 2014

Salmonella cases are not associated with Danish broiler meat, shows report

The number of Danes who contracted a salmonella infection reached a historic low level in 2013. More than half of those infected became ill during a trip abroad.

20 Jun 2014

DNA sequencing does not reveal the pathogenicity of bacteria

While more and more genomic information is becoming available at a drastically increasing pace, the knowledge we can gain about how microorganisms interact with their surrounding, infect hosts and alter their molecular programs in accordance to changing environmental conditions remains widely not deducible from genomic data alone, the researchers from University of Southern Denmark claim.

19 Jun 2014

Debiopharm launches Phase 1 study of anti-infective agent Debio 1450

Debiopharm Group, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).

19 Jun 2014

Research demonstrates association between diversity of gut bacteria and survival

New research, published online today in Blood, the Journal of the American Society of Hematology, suggests that the diversity of bacteria in the gastrointestinal tract of patients receiving stem cell transplants may be an important predictor of their post-transplant survival.

18 Jun 2014

Transfer of few immune cells can protect immunodeficient patients

The cells of the human immune system are created from special stem cells in the bone marrow. In diseases affecting the bone marrow, such as leukemia, the degenerate cells must be destroyed using radiation or chemotherapy.

18 Jun 2014

Fecal microbiota transplantation works by restoring healthy bacteria and functioning to recipient's gut

Fecal microbiota transplantation --- the process of delivering stool bacteria from a healthy donor to a patient suffering from intestinal infection with the bacterium Clostridium difficile --- works by restoring healthy bacteria and functioning to the recipient's gut, according to a study published this week in mBio-, the online open-access journal of the American Society for Microbiology.

17 Jun 2014

Enhancing vaccine efficiency through encapsulation

A work published in Vaccine, and led by the Institut de Biotecnologia i de Biomedicina (IBB – UAB) and ICN2, studies the biodistribution and immunological efficacy protecting from infection of immunostimulant-loaded nanoliposomes in zebrafish in vivo.

17 Jun 2014

Artificial sweetener have potential to limit impact of therapeutic drugs

One of the active ingredients in a popular artificial sweetener could have the potential to limit the impact of therapeutic drugs, reduce the number and balance of beneficial bacteria in the gut and alter hormone secretion, according to an article published in Journal of Toxicology and Environmental Health, Part A: Current Issues.

17 Jun 2014

Mechanisms of recurrent bacteria AOM in children under scrutiny

The immune response in young children with bacterial acute otitis media differs between individuals who are prone to such infection and those who are not, US researchers have shown.

16 Jun 2014

Investigators isolate protein that is responsible for fungus' ability to cross blood-brain barrier

In a remarkable series of experiments on a fungus that causes cryptococcal meningitis, a deadly infection of the membranes that cover the spinal cord and brain, investigators at UC Davis have isolated a protein that appears to be responsible for the fungus' ability to cross from the bloodstream into the brain.

13 Jun 2014

Findings provide new strategy for developing safe, effective vaccine against strep throat

An international team of scientists, led by researchers at the University of California, San Diego School of Medicine, have identified the genes encoding a molecule that famously defines Group A Streptococcus (strep), a pathogenic bacterial species responsible for more than 700 million infections worldwide each year.

12 Jun 2014

Ferrer recruits first patient in second phase III trial of Ozenoxacin for treatment of impetigo

Ferrer, a privately-held Spanish pharmaceutical company, today announces that the first patient has been recruited into a second phase III trial of Ozenoxacin, formulated as a topical treatment for infectious dermatological conditions in adult and paediatric patients with impetigo. The study is scheduled to complete in Q1, 2015.

12 Jun 2014

Bacterial News and Research

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

New wound treatment with material leads to faster healing, prevents harmful bacteria from sticking

Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Bruker receives CFDA clearance to market IVD MALDI Biotyper System in China

Alcoholic liver disease: an interview with Dr Vinood Patel, University of Westminster

Microparticles in crab, shrimp and lobster shells may help prevent inflammatory bowel disease

Scientists turn to old class of antibiotics to fight superbugs resistant to modern medicine

Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Salmonella cases are not associated with Danish broiler meat, shows report

DNA sequencing does not reveal the pathogenicity of bacteria

Debiopharm launches Phase 1 study of anti-infective agent Debio 1450

Research demonstrates association between diversity of gut bacteria and survival

Transfer of few immune cells can protect immunodeficient patients

Fecal microbiota transplantation works by restoring healthy bacteria and functioning to recipient's gut

Enhancing vaccine efficiency through encapsulation

Artificial sweetener have potential to limit impact of therapeutic drugs

Mechanisms of recurrent bacteria AOM in children under scrutiny

Investigators isolate protein that is responsible for fungus' ability to cross blood-brain barrier

Findings provide new strategy for developing safe, effective vaccine against strep throat

Ferrer recruits first patient in second phase III trial of Ozenoxacin for treatment of impetigo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News